On October 3, the FDA approved coformulated tenofovir alafenamide and emtricitabine (F/TAF) for HIV prevention in at-risk “adults and adolescents…excluding those who have receptive vaginal sex.” F/TAF’s story highlights numerous flaws in the drug-approval process.